Alimera Sciences 주식 주식분석 | 주식가격 | 뉴스 | ALIM | US0162592028 | A2PVHE

날짜	Alimera Sciences 주식 가격
	5.59 undefined
	5.58 undefined
	5.59 undefined
	5.58 undefined
	5.59 undefined
	5.58 undefined
	5.58 undefined
	5.59 undefined
	5.60 undefined
	5.60 undefined
	5.59 undefined
	5.57 undefined
	5.55 undefined
	5.55 undefined
	5.55 undefined
	5.56 undefined
	5.56 undefined
	5.56 undefined
	5.55 undefined
	5.56 undefined

날짜	Alimera Sciences 매출	Alimera Sciences EBIT	Alimera Sciences 이익
2029e	278.83 백만 undefined	0 undefined	108.48 백만 undefined
2028e	234.04 백만 undefined	102.83 백만 undefined	83.36 백만 undefined
2027e	195.32 백만 undefined	72.89 백만 undefined	53.97 백만 undefined
2026e	138.63 백만 undefined	33.41 백만 undefined	22.98 백만 undefined
2025e	123.51 백만 undefined	19.71 백만 undefined	10.15 백만 undefined
2024e	108.13 백만 undefined	5.06 백만 undefined	-6.77 백만 undefined
2023	80.75 백만 undefined	-1.93 백만 undefined	-21.39 백만 undefined
2022	54.13 백만 undefined	-11.64 백만 undefined	-18.11 백만 undefined
2021	59.03 백만 undefined	-200,000 undefined	-4.37 백만 undefined
2020	50.82 백만 undefined	-500,000 undefined	-5.34 백만 undefined
2019	53.94 백만 undefined	-5.27 백만 undefined	-10.44 백만 undefined
2018	46.6 백만 undefined	-9.67 백만 undefined	21.95 백만 undefined
2017	35.91 백만 undefined	-16.45 백만 undefined	-22 백만 undefined
2016	34.33 백만 undefined	-27.85 백만 undefined	-33.17 백만 undefined
2015	22.44 백만 undefined	-39 백만 undefined	-30.65 백만 undefined
2014	8.42 백만 undefined	-32.95 백만 undefined	-36.66 백만 undefined
2013	1.87 백만 undefined	-34.41 백만 undefined	-51.18 백만 undefined
2012	0 undefined	-22.04 백만 undefined	-19.75 백만 undefined
2011	0 undefined	-21.41 백만 undefined	-22.52 백만 undefined
2010	0 undefined	-22.07 백만 undefined	-16.96 백만 undefined
2009	0 undefined	-19.22 백만 undefined	-52.42 백만 undefined
2008	0 undefined	-50.08 백만 undefined	-68.76 백만 undefined
2007	0 undefined	-12.52 백만 undefined	-10.64 백만 undefined
2006	0 undefined	-10.38 백만 undefined	-16.76 백만 undefined
2005	0 undefined	-6.08 백만 undefined	-15.35 백만 undefined
2004	0 undefined	-3.82 백만 undefined	-7.11 백만 undefined

	매출	EBIT	이익
2004	0 USD	-3.82 백만 USD	-7.11 백만 USD
2005	0 USD	-6.08 백만 USD	-15.35 백만 USD
2006	0 USD	-10.38 백만 USD	-16.76 백만 USD
2007	0 USD	-12.52 백만 USD	-10.64 백만 USD
2008	0 USD	-50.08 백만 USD	-68.76 백만 USD
2009	0 USD	-19.22 백만 USD	-52.42 백만 USD
2010	0 USD	-22.07 백만 USD	-16.96 백만 USD
2011	0 USD	-21.41 백만 USD	-22.52 백만 USD
2012	0 USD	-22.04 백만 USD	-19.75 백만 USD
2013	1.87 백만 USD	-34.41 백만 USD	-51.18 백만 USD
2014	8.42 백만 USD	-32.95 백만 USD	-36.66 백만 USD
2015	22.44 백만 USD	-39 백만 USD	-30.65 백만 USD
2016	34.33 백만 USD	-27.85 백만 USD	-33.17 백만 USD
2017	35.91 백만 USD	-16.45 백만 USD	-22 백만 USD
2018	46.6 백만 USD	-9.67 백만 USD	21.95 백만 USD
2019	53.94 백만 USD	-5.27 백만 USD	-10.44 백만 USD
2020	50.82 백만 USD	-500,000 USD	-5.34 백만 USD
2021	59.03 백만 USD	-200,000 USD	-4.37 백만 USD
2022	54.13 백만 USD	-11.64 백만 USD	-18.11 백만 USD
2023	80.75 백만 USD	-1.93 백만 USD	-21.39 백만 USD
2024e	108.13 백만 USD	5.06 백만 USD	-6.77 백만 USD
2025e	123.51 백만 USD	19.71 백만 USD	10.15 백만 USD
2026e	138.63 백만 USD	33.41 백만 USD	22.98 백만 USD
2027e	195.32 백만 USD	72.89 백만 USD	53.97 백만 USD
2028e	234.04 백만 USD	102.83 백만 USD	83.36 백만 USD
2029e	278.83 백만 USD	0 USD	108.48 백만 USD

2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

27.2	20.8	17.9	4.9	54.8	33.6	49.6	12.6	76.7	31.1	31	24.1	13	9.4	11.2	16.5	5.3	12.06
0.5	0.1	0	0	0	0	0	0.5	0.9	9.8	13.8	11.4	17.3	19.3	17.2	19.1	19.6	34.55
0.7	1.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0.7	0	0	0	0	0	0.7	1.8	1.7	1.6	0.4	1.5	2.4	1.4	2.7	2.7	1.6	1.88
1.7	1.3	1.6	1.4	1.4	0.9	2.1	3.8	3.2	2.7	2.1	2.3	2.1	2.6	3.7	3.8	2.9	3.94
30.8	24.1	19.5	6.3	56.2	34.5	52.4	18.7	82.5	45.2	47.3	39.3	34.8	32.7	34.8	42.1	29.4	52.42
0.4	0.4	0.8	0.3	0.2	0.2	0.1	1	1.7	2.6	1.8	1.4	1.4	2	2.4	4.5	3.9	3.59
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	800	200	52
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	24.5	22.5	20.6	18.7	16.7	14.8	12.8	10.9	9	97.36
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0.2	0.4	0.5	1.2	0.7	0.8	0.1	0.1	0.1
0.4	0.4	0.8	0.3	0.2	0.2	0.1	1	26.2	25.3	22.8	20.6	19.3	17.5	16	16.3	13.2	101.1
31.2	24.5	20.3	6.6	56.4	34.7	52.5	19.7	108.7	70.5	70.1	59.9	54.1	50.2	50.8	58.4	42.6	153.52

63.1	68.1	103.1	113.5	0.3	0.3	32.3	32.3	69.2	69.3	69.4	69.5	31	30.4	19.3	19.3	19.3	0.52
2.6	2.9	3.5	6.3	233.3	235.6	237.5	240.1	292.9	299.4	330.8	341.6	346.1	350.1	365.8	377.2	378.2	462.45
-40	-50.7	-119.4	-171.8	-188.4	-211	-230.7	-276.9	-311.8	-341.2	-373.4	-395.4	-373.4	-383.9	-392.5	-397.3	-415.4	-414.09
0	0	0	0	0	0	0	-0.5	-0.8	-1.1	-1.3	-0.8	-1	-1.1	-0.6	-1.8	-3	-2.71
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
25.7	20.3	-12.8	-52	45.2	24.9	39.1	-5	49.5	26.4	25.5	14.9	2.7	-4.5	-8	-2.6	-20.9	46.17
1.7	0.8	1.6	1.8	1.7	1.9	2	1.7	5	4	5	5.9	6.4	7.1	7.5	8.7	10.1	8.25
2	2.8	2.3	3.3	2.7	1.6	1.2	0.9	3	3.6	3.8	3.6	3.6	4.7	3.2	3.6	4	13.47
1.9	0.6	1	1.2	0.8	0.7	2.6	0.6	1.5	0.3	0.2	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	4.5	1.2	2.5	2.3	1.7	1	32	0.2	0.2	0.2	0.3	1.7	0.3	25.6	0.19
5.6	4.2	4.9	10.8	6.4	6.7	8.1	4.9	10.5	39.9	9.2	9.7	10.2	12.1	12.4	12.6	39.7	21.91
0	0	15	10.5	4.8	2.9	0.7	3.2	32.3	0.6	33.4	34.6	38.2	38.8	42.9	43.1	18.7	64.49
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	13.2	37.4	0	0.1	4.6	16.4	16.3	3.6	2.2	0.8	3	4	3.6	5.5	5	20.95
0	0	28.2	47.9	4.8	3	5.3	19.6	48.6	4.2	35.6	35.4	41.2	42.8	46.5	48.6	23.7	85.44
5.6	4.2	33.1	58.7	11.2	9.7	13.4	24.5	59.1	44.1	44.8	45.1	51.4	54.9	58.9	61.2	63.4	107.35
31.3	24.5	20.3	6.7	56.4	34.6	52.5	19.5	108.6	70.5	70.3	60	54.1	50.4	50.9	58.6	42.5	153.52

2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
-13	-12	-5	-61	-44	-13	-22	-19	-46	-35	-30	-33	-22	-16	-10	-5	-4	-18	-20
0	0	0	0	1	0	0	0	0	0	2	2	2	2	2	2	2	2	8
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	1	0	0	0	-6	5	-10	0	0	-4	0	-1	-1	2	-15
0	-7	-7	29	24	-7	4	0	16	8	-1	10	11	11	5	3	0	3	14
0	0	0	0	1	0	0	0	0	1	4	3	4	3	4	4	4	4	6
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-12	-20	-12	-32	-17	-22	-20	-21	-37	-24	-45	-25	-12	-11	-4	-2	-3	-9	-14
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-75
0	9	6	0	0	-22	25	0	0	-25	0	0	0	0	0	0	0	0	-75
0	9	6	0	0	-22	25	0	0	-25	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	-8	0	-2	1	29	0	0	0	4	2	3	0	0	22
32	15	0	29	4	79	0	40	0	85	1	26	5	0	0	0	10	0	79
32	15	0	29	4	68	0	37	1	114	0	25	5	0	0	3	9	0	96
-	-	-	-	-	-2.00	-	-	-	-1.00	-	-1.00	-	-3.00	-2.00	-	-	-	-5.00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
19	4	-6	-2	-13	23	4	16	-36	64	-45	0	-6	-11	-3	1	5	-11	6
-13.09	-21.22	-13.11	-32.76	-17.61	-22.18	-20.83	-21.2	-38.79	-25.14	-45.81	-25.29	-13.11	-11.73	-4.32	-2.81	-3.84	-10.24	-89.79
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Alimera Sciences 브루토마진	Alimera Sciences 이익 마진	Alimera Sciences EBIT-마진	Alimera Sciences 이익 마진
2029e	86.58 %	0 %	38.9 %
2028e	86.58 %	43.94 %	35.62 %
2027e	86.58 %	37.32 %	27.63 %
2026e	86.58 %	24.1 %	16.58 %
2025e	86.58 %	15.95 %	8.22 %
2024e	86.58 %	4.68 %	-6.26 %
2023	86.58 %	-2.39 %	-26.49 %
2022	85.26 %	-21.5 %	-33.46 %
2021	88.09 %	-0.34 %	-7.4 %
2020	86.34 %	-0.98 %	-10.51 %
2019	87.73 %	-9.77 %	-19.35 %
2018	90.75 %	-20.75 %	47.1 %
2017	90.42 %	-45.81 %	-61.26 %
2016	93.18 %	-81.12 %	-96.62 %
2015	92.16 %	-173.8 %	-136.59 %
2014	82.9 %	-391.33 %	-435.39 %
2013	0.53 %	-1,840.11 %	-2,736.9 %
2012	86.58 %	0 %	0 %
2011	86.58 %	0 %	0 %
2010	86.58 %	0 %	0 %
2009	86.58 %	0 %	0 %
2008	86.58 %	0 %	0 %
2007	86.58 %	0 %	0 %
2006	86.58 %	0 %	0 %
2005	86.58 %	0 %	0 %
2004	86.58 %	0 %	0 %

	브루토마진	EBIT-마진	이익 마진
2004	86.58 %	0 %	0 %
2005	86.58 %	0 %	0 %
2006	86.58 %	0 %	0 %
2007	86.58 %	0 %	0 %
2008	86.58 %	0 %	0 %
2009	86.58 %	0 %	0 %
2010	86.58 %	0 %	0 %
2011	86.58 %	0 %	0 %
2012	86.58 %	0 %	0 %
2013	0.53 %	-1,840.11 %	-2,736.9 %
2014	82.9 %	-391.33 %	-435.39 %
2015	92.16 %	-173.8 %	-136.59 %
2016	93.18 %	-81.12 %	-96.62 %
2017	90.42 %	-45.81 %	-61.26 %
2018	90.75 %	-20.75 %	47.1 %
2019	87.73 %	-9.77 %	-19.35 %
2020	86.34 %	-0.98 %	-10.51 %
2021	88.09 %	-0.34 %	-7.4 %
2022	85.26 %	-21.5 %	-33.46 %
2023	86.58 %	-2.39 %	-26.49 %
2024e	86.58 %	4.68 %	-6.26 %
2025e	86.58 %	15.95 %	8.22 %
2026e	86.58 %	24.1 %	16.58 %
2027e	86.58 %	37.32 %	27.63 %
2028e	86.58 %	43.94 %	35.62 %
2029e	86.58 %	0 %	38.9 %

날짜	Alimera Sciences 주당 매출	Alimera Sciences EBIT 당 주식	Alimera Sciences 주당 이익
2029e	5.32 undefined	0 undefined	2.07 undefined
2028e	4.47 undefined	0 undefined	1.59 undefined
2027e	3.73 undefined	0 undefined	1.03 undefined
2026e	2.65 undefined	0 undefined	0.44 undefined
2025e	2.36 undefined	0 undefined	0.19 undefined
2024e	2.06 undefined	0 undefined	-0.13 undefined
2023	3.16 undefined	-0.08 undefined	-0.84 undefined
2022	7.73 undefined	-1.66 undefined	-2.59 undefined
2021	8.94 undefined	-0.03 undefined	-0.66 undefined
2020	9.93 undefined	-0.1 undefined	-1.04 undefined
2019	11.31 undefined	-1.1 undefined	-2.19 undefined
2018	7.87 undefined	-1.63 undefined	3.71 undefined
2017	0.54 undefined	-0.25 undefined	-0.33 undefined
2016	0.65 undefined	-0.53 undefined	-0.63 undefined
2015	0.5 undefined	-0.88 undefined	-0.69 undefined
2014	0.21 undefined	-0.82 undefined	-0.91 undefined
2013	0.06 undefined	-1.09 undefined	-1.62 undefined
2012	0 undefined	-0.7 undefined	-0.63 undefined
2011	0 undefined	-0.68 undefined	-0.72 undefined
2010	0 undefined	-1 undefined	-0.76 undefined
2009	0 undefined	-12.64 undefined	-34.49 undefined
2008	0 undefined	-33.17 undefined	-45.54 undefined
2007	0 undefined	-8.35 undefined	-7.09 undefined
2006	0 undefined	-2.12 undefined	-3.43 undefined
2005	0 undefined	-1.24 undefined	-3.14 undefined
2004	0 undefined	-0.78 undefined	-1.45 undefined

	주당 매출	EBIT 당 주식	주당 이익
2004	0 USD	-0.78 USD	-1.45 USD
2005	0 USD	-1.24 USD	-3.14 USD
2006	0 USD	-2.12 USD	-3.43 USD
2007	0 USD	-8.35 USD	-7.09 USD
2008	0 USD	-33.17 USD	-45.54 USD
2009	0 USD	-12.64 USD	-34.49 USD
2010	0 USD	-1 USD	-0.76 USD
2011	0 USD	-0.68 USD	-0.72 USD
2012	0 USD	-0.7 USD	-0.63 USD
2013	0.06 USD	-1.09 USD	-1.62 USD
2014	0.21 USD	-0.82 USD	-0.91 USD
2015	0.5 USD	-0.88 USD	-0.69 USD
2016	0.65 USD	-0.53 USD	-0.63 USD
2017	0.54 USD	-0.25 USD	-0.33 USD
2018	7.87 USD	-1.63 USD	3.71 USD
2019	11.31 USD	-1.1 USD	-2.19 USD
2020	9.93 USD	-0.1 USD	-1.04 USD
2021	8.94 USD	-0.03 USD	-0.66 USD
2022	7.73 USD	-1.66 USD	-2.59 USD
2023	3.16 USD	-0.08 USD	-0.84 USD
2024e	2.06 USD	0 USD	-0.13 USD
2025e	2.36 USD	0 USD	0.19 USD
2026e	2.65 USD	0 USD	0.44 USD
2027e	3.73 USD	0 USD	1.03 USD
2028e	4.47 USD	0 USD	1.59 USD
2029e	5.32 USD	0 USD	2.07 USD

	주식 수량
2004	4.89 백만 Aktien
2005	4.89 백만 Aktien
2006	4.89 백만 Aktien
2007	1.5 백만 Aktien
2008	1.51 백만 Aktien
2009	1.52 백만 Aktien
2010	22.17 백만 Aktien
2011	31.36 백만 Aktien
2012	31.46 백만 Aktien
2013	31.58 백만 Aktien
2014	40.4 백만 Aktien
2015	44.45 백만 Aktien
2016	52.8 백만 Aktien
2017	66.99 백만 Aktien
2018	5.92 백만 Aktien
2019	4.77 백만 Aktien
2020	5.12 백만 Aktien
2021	6.6 백만 Aktien
2022	7 백만 Aktien
2023	25.56 백만 Aktien
2024e	25.56 백만 Aktien
2025e	25.56 백만 Aktien
2026e	25.56 백만 Aktien
2027e	25.56 백만 Aktien
2028e	25.56 백만 Aktien
2029e	25.56 백만 Aktien

EPS-예상치	EPS-실제	보고 분기
-0.04	-0.06 (-60.43 %)	2024 Q2
-0.06	-0.12 (-107.61 %)	2024 Q1
0	-0.07 (0 %)	2023 Q4
-0.07	-0.06 (8.81 %)	2023 Q3
0.02	-1.32 (-8,727.45 %)	2023 Q2
-0.33	-0.71 (-117.52 %)	2023 Q1
-0.34	-0.54 (-58.03 %)	2022 Q4
-0.41	-0.75 (-82.3 %)	2022 Q3
-0.56	-0.45 (20.27 %)	2022 Q2
-0.7	-0.85 (-20.77 %)	2022 Q1
-0.43	-0.59 (-37.72 %)	2021 Q4
-0.54	-0.6 (-12.04 %)	2021 Q3
1.08	0.72 (-33.41 %)	2021 Q2
-0.55	-0.63 (-14.38 %)	2021 Q1
-0.04	-0.18 (-307.24 %)	2020 Q4
-0.45	-0.12 (73.46 %)	2020 Q3
-1.65	-0.51 (69.04 %)	2020 Q2
-0.44	-0.24 (45.6 %)	2020 Q1
-0.46	0.08 (117.35 %)	2019 Q4
-0.61	-0.6 (1.96 %)	2019 Q3
-0.56	-1.05 (-87.13 %)	2019 Q2
-0.64	-0.6 (6.63 %)	2019 Q1
-0.46	-0.3 (34.64 %)	2018 Q4
-0.95	-0.75 (20.94 %)	2018 Q3
-0.95	-0.9 (5.12 %)	2018 Q2
-0.84	-1.65 (-96.08 %)	2018 Q1
-0.65	-1.5 (-130.66 %)	2017 Q4
-0.69	-1.8 (-161.44 %)	2017 Q3
-0.8	-0.6 (25.31 %)	2017 Q2
-1.26	-1.5 (-18.83 %)	2017 Q1
-1.12	-1.35 (-20.33 %)	2016 Q4
-1.73	-2.4 (-38.42 %)	2016 Q3
-2.91	-2.25 (22.6 %)	2016 Q2
-2.75	-3.3 (-19.83 %)	2016 Q1
-3.32	-3.6 (-8.59 %)	2015 Q4
-3.21	-0.45 (85.99 %)	2015 Q3
-3.32	-2.85 (14.03 %)	2015 Q2
-3.67	-3.3 (10.13 %)	2015 Q1
-2.55	-3.45 (-35.29 %)	2014 Q4
-10.71	-2.55 (76.19 %)	2014 Q3
-3.44	0.6 (117.43 %)	2014 Q2
-3.75	-3 (19.97 %)	2014 Q1
-4.36	-6.3 (-44.48 %)	2013 Q4
-4.51	-3.9 (13.59 %)	2013 Q3
-3.67	-4.5 (-22.55 %)	2013 Q2
-4.05	-4.05 (0.11 %)	2013 Q1
-3.52	-2.55 (27.54 %)	2012 Q4
-2.75	-2.55 (7.41 %)	2012 Q3
-2.49	-2.25 (9.5 %)	2012 Q2
-1.9	-2.1 (-10.69 %)	2012 Q1
-3.4	-2.85 (16.28 %)	2011 Q4
-2.91	-3.15 (-8.36 %)	2011 Q3
-2.97	-2.55 (14.09 %)	2011 Q2
-2.98	-2.25 (24.59 %)	2011 Q1
-3.4	-3 (11.88 %)	2010 Q4
-4.02	-3 (25.3 %)	2010 Q3
-4.02	-4.05 (-0.84 %)	2010 Q2
-7.5	-65.55 (-774.35 %)	2010 Q1

%-지분	이름	주식	변경
7.63 %	Stonepine Capital Management, LLC	3,999,459	15,773
6.11 %	Boothbay Fund Management, LLC	3,198,708	0
5.08 %	Altium Capital Management LP	2,660,000	-274,108
4.17 %	Lytton (Laurence W)	2,185,364	-799,439
4.14 %	Clearline Capital LP	2,169,143	-166,150
32.13 %	Caligan Partners, LP	16,835,154	0
3.19 %	AIGH Capital Management, LLC.	1,669,426	-109,437
25.98 %	Velan Capital Investment Management LP	13,608,533	0
2.19 %	Ocumension Therapeutics	1,144,945	0
1.74 %	Morgan Stanley & Co. LLC	910,832	250,000
1.38 %	Eiswirth (Richard S Jr)	722,518	400,000
1.24 %	The Vanguard Group, Inc.	648,954	502,268
1.06 %	Worth Venture Partners, LLC	556,642	-37,067
0.89 %	HBM Partners AG	466,666	466,666
0.73 %	BlackRock Institutional Trust Company, N.A.	383,713	383,236
0.63 %	Geode Capital Management, L.L.C.	331,977	279,153
0.43 %	Werner (Jason M.)	225,921	225,000
0.30 %	Renaissance Technologies LLC	158,794	45,900
0.24 %	BMO Capital Markets (US)	124,297	124,297
0.23 %	Ashman Philip	118,274	-12,103
0.21 %	Susquehanna International Group, LLP	110,610	110,610
0.21 %	Holland (David R)	108,800	-80
0.14 %	Skibsted (Russell L)	75,500	58,000
0.08 %	Balyasny Asset Management LP	40,032	40,032
0.06 %	Millennium Management LLC	32,461	-57,350
0.06 %	Jones (John Philip)	32,186	372
0.06 %	BlackRock (Netherlands) B.V.	31,783	31,783
0.06 %	Citi Investment Research (US)	30,808	29,208
0.05 %	Hightower Advisors, LLC	25,091	25,091
0.04 %	BofA Global Research (US)	20,796	18,296
0.04 %	Bridgeway Capital Management, LLC	20,000	0
0.04 %	Citadel Advisors LLC	19,874	19,874
0.04 %	ExodusPoint Capital Management, LP	19,376	19,376
0.03 %	BlackRock Advisors (UK) Limited	16,769	16,769
0.03 %	Northern Trust Investments, Inc.	14,132	14,132
0.02 %	Jefferies LLC	12,900	0
0.01 %	BlackRock Investment Management (UK) Ltd.	7,055	7,055
0.01 %	Morgan Stanley Smith Barney LLC	5,414	0
0.01 %	Acadian Asset Management LLC	5,263	-2,410
0.01 %	BlackRock Investment Management, LLC	4,519	4,461
0.01 %	Osaic Holdings, Inc.	4,065	0
0.00 %	Tower Research Capital LLC	300	-11,700
0.00 %	Wells Fargo Bank, N.A.	282	243
0.00 %	Syntax Research, Inc.	80	0
0.00 %	Focused Wealth Management, Inc.	66	0
0.00 %	J.P. Morgan Securities LLC	61	-4,679
0.00 %	RBC Capital Partners	22	-23
0.00 %	Comerica, Inc.	14	0
0.00 %	UBS Financial Services, Inc.	2	2
0 %	Pizzo (Peter J III)	0	-500
0 %	DWS Investments UK Limited	0	-28,052
0 %	Myers (C Daniel)	0	-5,578
0 %	Barclays Capital Inc.	0	-36
0 %	Ancora Advisors, L.L.C.	0	-333
0 %	Palo Alto Investors LP	0	-200,919
0 %	Perritt Capital Management, Inc.	0	-10,000
0 %	Optimum Investment Advisors, LLC	0	-4,108
0 %	HOOPP Investment Management	0	-250,000
0 %	Gabelli Funds, LLC	0	-4,000
0 %	Dimensional Fund Advisors, L.P.	0	-1,754
0 %	Morgan (Adam)	0	-912
0 %	Money Concepts Capital Corp	0	-60
0 %	Snisarenko (John)	0	-10,000

What values and corporate philosophy does Alimera Sciences represent?

Alimera Sciences Inc represents a commitment to improving the lives of patients with retinal diseases. The company is dedicated to developing and commercializing innovative prescription products that address the unmet medical needs in ophthalmology. Alimera Sciences focuses on the development of sustained-release treatments, such as ILUVIEN®, which is designed to provide long-term reduction of vision loss associated with diabetic macular edema. With a patient-centric approach, Alimera Sciences strives to enhance visual outcomes and quality of life for individuals worldwide. The company's corporate philosophy emphasizes scientific excellence, ethical behavior, and a dedication to advancing eye care through research and development.

In which countries and regions is Alimera Sciences primarily present?

Alimera Sciences Inc is primarily present in the United States, Europe, and the Middle East.

What significant milestones has the company Alimera Sciences achieved?

Alimera Sciences Inc has achieved significant milestones since its inception. Notably, the company has successfully developed and commercialized ILUVIEN, a sustained-release intravitreal implant for the treatment of diabetic macular edema (DME). This innovative product has been approved by regulatory authorities in various countries, including Europe and the United States. Additionally, Alimera Sciences Inc has expanded its market reach through strategic partnerships and collaborations with influential pharmaceutical companies. The company's commitment to ongoing research and development has led to advancements in ocular drug delivery systems, positioning Alimera Sciences Inc as a leading player in the ophthalmic pharmaceutical industry.

What is the history and background of the company Alimera Sciences?

Alimera Sciences Inc. is a pharmaceutical company established in 2003 and headquartered in Atlanta, Georgia. It specializes in developing and commercializing prescription ophthalmology products for the treatment of retinal diseases. Alimera Sciences Inc. is primarily known for its flagship product, ILUVIEN®, which is an injectable steroid implant used for the treatment of diabetic macular edema (DME) in patients who have been previously treated but have not responded adequately to other therapies. With its innovative products and focus on retinal diseases, Alimera Sciences Inc. continues to make significant contributions to the healthcare industry.

Who are the main competitors of Alimera Sciences in the market?

The main competitors of Alimera Sciences Inc in the market are pharmaceutical companies that specialize in ophthalmology and the treatment of various eye diseases. Some of the prominent competitors include BioSpecifics Technologies Corp, Eyenovia Inc, Ocular Therapeutix Inc, and Novartis AG. These companies also offer innovative solutions, products, and therapies for eye conditions, competing with Alimera Sciences Inc in the ophthalmic pharmaceutical market.

In which industries is Alimera Sciences primarily active?

Alimera Sciences Inc is primarily active in the pharmaceutical industry.

What is the business model of Alimera Sciences?

The business model of Alimera Sciences Inc is focused on the research, development, and commercialization of ophthalmic pharmaceuticals. The company specializes in offering innovative treatments for retinal diseases, primarily diabetic macular edema (DME), a leading cause of vision loss. Alimera Sciences Inc primarily operates through its flagship product, ILUVIEN, which is a sustained-release intravitreal implant designed to deliver a continuous, low-dose of medication to the retina over an extended period. By providing long-lasting therapies, Alimera Sciences Inc aims to improve patient outcomes and reduce treatment burdens. With a devoted focus on retinal diseases, the company continues to expand its portfolio and enhance the quality of life for individuals with vision impairments.

Alimera Sciences 2024의 P/E 비율은 얼마입니까?

Alimera Sciences의 P/E 비율은 -21.11입니다.

Alimera Sciences 2024의 KUV는 얼마입니까?

Alimera Sciences의 P/S 비율은 1.32입니다.

Alimera Sciences의 AlleAktien 품질 점수는 얼마인가요?

Alimera Sciences에 대한 AlleAktien 품질 점수는 5/10입니다.

Alimera Sciences 2024의 매출은 얼마인가요?

예상되는 Alimera Sciences 매출은 108.13 백만 USD입니다.

Alimera Sciences 2024의 이익은 얼마인가요?

예상되는 Alimera Sciences 이익은 -6.77 백만 USD입니다.

Alimera Sciences은 무엇을 하나요?

Alimera Sciences Inc is a biopharmaceutical company based in Georgia that specializes in the development and commercialization of therapies for eye diseases. The company was founded in 2003 and has since built various collaborations and partnerships with other companies. Alimera Sciences specializes in the development of medications for eye diseases, particularly Diabetic Macular Edema (DME) and Uveitis. The company's flagship product is ILUVIEN®, an intravitreal implant that continuously releases the glucocorticoid fluocinolone acetonide to slow the progression of vision loss. ILUVIEN® was approved in the United States in 2012 and has been on the market in Europe since 2013. Alimera Sciences Inc. serves a rapidly growing market as diabetic retinopathy and age-related macular degeneration (AMD) increasingly lead to significant impairments in vision. However, treating diabetic retinopathy and AMD is very challenging, and there are concerns about the safety and effectiveness of existing therapies. Alimera Sciences' business model is based on developing and bringing to market innovative medications and therapies that address the gaps in existing treatment options. The company works closely with other companies and research institutions to develop new technologies and treatment approaches. Alimera Sciences has established several marketing partnerships in various countries to distribute its products worldwide. The company has entered into strategic partnerships with major pharmaceutical companies such as Bausch + Lomb, Brill Pharma, and Mundipharma to enable broader marketing of ILUVIEN®. The company has also focused on researching and developing new technologies and therapies to harness the potential in other eye diseases, such as Uveitis. The company recently launched a novel antiviral therapy for Uveitis, which is still in the clinical trial stage. Alimera Sciences also maintains a pipeline of drugs in various stages of development to expand its portfolio of eye therapies. Alimera Sciences has experienced significant growth in recent years. The company achieved a net revenue of $51 million in 2019 and expects further growth in the coming years through the introduction of new products and expansion of its geographical reach. Overall, Alimera Sciences is a biopharmaceutical company specializing in the development and commercialization of therapies for eye diseases. The company has developed an innovative portfolio of products and technologies tailored to the needs of the rapidly growing market. Alimera Sciences has established strategic partnerships to facilitate the global marketing of its products. The company maintains a strong pipeline of drugs in various stages of development aimed at further closing the gaps in existing treatment options.

Alimera Sciences 배당금은 얼마입니까?

Alimera Sciences은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Alimera Sciences이 얼마나 자주 배당을 지급하나요?

Alimera Sciences의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Alimera Sciences ISIN이 무엇입니까?

Alimera Sciences의 ISIN은 US0162592028입니다.

Alimera Sciences WKN은 무엇인가요?

Alimera Sciences의 WKN은 A2PVHE입니다.

Alimera Sciences 티커는 무엇인가요?

Alimera Sciences의 티커는 ALIM입니다.

Alimera Sciences이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 Alimera Sciences은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Alimera Sciences은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Alimera Sciences의 배당 수익률은 얼마입니까?

Alimera Sciences의 현재 배당 수익률은 입니다.

Alimera Sciences의 배당금은 언제 지급되나요?

Alimera Sciences은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Alimera Sciences의 배당금은 얼마나 안전한가요?

Alimera Sciences은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

Alimera Sciences의 배당금은 얼마입니까?

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Alimera Sciences이(가) 속해 있는 섹터는 어디인가요?

Alimera Sciences은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von Alimera Sciences kaufen, um die vorherige Dividende zu erhalten?

Alimera Sciences의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

Alimera Sciences의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

Alimera Sciences의 2023년도 배당금은 얼마였습니까?

2023년에 Alimera Sciences는 0 USD를 배당금으로 지급했습니다.

Alimera Sciences는 어떤 화폐로 배당금을 지급하나요?

Alimera Sciences의 배당금은 USD에 지급됩니다.

증권거래소	Alimera Sciences 티커
뒤셀도르프	ASZ1.DU
프랑크푸르트	ASZ1.F
NASDAQ	ALIM

Alimera Sciences 티커	Alimera Sciences FIGI
ALIM:US	BBG000QLS2G2
ALIM:UA	BBG000QLS2P2
ALIM:UC	BBG000QLS2T8
ALIM:UN	BBG000QLS389
ALIM:UP	BBG000QLS3M3
ALIM:UQ	BBG000QLS405
ALIM:UB	BBG000QLS478
ALIM:UM	BBG000QLS4W0
ALIM:UX	BBG000QLS557
ALIM:UD	BBG000QLS968
ALIM:UF	BBG000QLSC43
ALIM:VY	BBG000QLSCB5
ALIM:VJ	BBG000QLSCG0
ALIM:VK	BBG000QLSD23
ASZ1:GR	BBG000W3VBN3
ASZ1:GF	BBG000W3VBZ0
ASZ1:GD	BBG000W3VC51
ASZ1:GS	BBG000W3VCD2
ASZ1:GB	BBG000W3VCP9
ASZ1:TH	BBG000WGMS20
ALIMEUR:XH	BBG00DJ642N3
ALIMEUR:XF	BBG00DJ642Q0
ALIMEUR:XE	BBG00DJ642S8
ALIMEUR:XL	BBG00DJ642V4
ALIMEUR:XG	BBG00DJ642W3
ALIMEUR:XO	BBG00DJ642X2
ALIMEUR:XA	BBG00DJ64324
ALIMEUR:XT	BBG00DJ64342
ALIMEUR:XW	BBG00DJ64351
ALIMEUR:XU	BBG00DJ64360
ALIMEUR:XV	BBG00DJ64379
ALIMEUR:EU	BBG00DJ64397
ALIM:VF	BBG00DJGJ6D7
ALIMUSD:XH	BBG00JPD1RP4
ALIMUSD:XF	BBG00JPD1RR2
ALIMUSD:XE	BBG00JPD1RT0
ALIMUSD:XL	BBG00JPD1RW6
ALIMUSD:XG	BBG00JPD1RX5
ALIMUSD:XO	BBG00JPD1RY4
ALIMUSD:XA	BBG00JPD1S36
ALIMUSD:XT	BBG00JPD1S54
ALIMUSD:XW	BBG00JPD1S63
ALIMUSD:XU	BBG00JPD1S72
ALIMUSD:XV	BBG00JPD1S81
ALIMUSD:XM	BBG00JPD1S90
ALIMUSD:EU	BBG00JPD1SH1
ALIMGBP:XH	BBG00KDXQ6C3
ALIMGBP:XF	BBG00KDXQ6F0
ALIMGBP:XE	BBG00KDXQ6H8
ALIMGBP:XL	BBG00KDXQ6K4
ALIMGBP:XG	BBG00KDXQ6L3
ALIMGBP:XO	BBG00KDXQ6M2
ALIMGBP:XA	BBG00KDXQ6S6
ALIMGBP:XT	BBG00KDXQ6V2
ALIMGBP:XW	BBG00KDXQ6W1
ALIMGBP:XU	BBG00KDXQ6X0
ALIMGBP:XV	BBG00KDXQ6Y9
ALIMGBP:XM	BBG00KDXQ6Z8
ALIMGBP:EU	BBG00KDXQ759
ALIM:VG	BBG00X1NT6K8
ALIM:VP	BBG00X1S7QL6
ASZ1:LA	BBG018H92705
ASZ1:LU	BBG018J2Q7W7
ASZ1:QT	BBG01FN0FFB7
ASZ1:GZ	BBG01JXFQ1P9

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e
0	0	0	0	0	0	0	0	0	0	1	8	22	34	35	46	53	50	59	54	80	108	123	138	195	234	278
-	-	-	-	-	-	-	-	-	-	-	700.00	175.00	54.55	2.94	31.43	15.22	-5.66	18.00	-8.47	48.15	35.00	13.89	12.20	41.30	20.00	18.80
-	-	-	-	-	-	-	-	-	-	-	75.00	90.91	91.18	91.43	91.30	88.68	86.00	88.14	85.19	86.25	-	-	-	-	-	-
0	0	0	0	0	0	0	0	0	0	0	6	20	31	32	42	47	43	52	46	69	0	0	0	0	0	0
0	-3	-6	-10	-12	-50	-19	-22	-21	-22	-34	-32	-39	-27	-16	-9	-5	0	0	-11	-1	5	19	33	72	102	0
-	-	-	-	-	-	-	-	-	-	-3,400.00	-400.00	-177.27	-79.41	-45.71	-19.57	-9.43	-	-	-20.37	-1.25	4.63	15.45	23.91	36.92	43.59	-
0	-7	-15	-16	-10	-68	-52	-16	-22	-19	-51	-36	-30	-33	-22	21	-10	-5	-4	-18	-21	-6	10	22	53	83	108
-	-	114.29	6.67	-37.50	580.00	-23.53	-69.23	37.50	-13.64	168.42	-29.41	-16.67	10.00	-33.33	-195.45	-147.62	-50.00	-20.00	350.00	16.67	-71.43	-266.67	120.00	140.91	56.60	30.12
4.89	4.89	4.89	4.89	1.5	1.51	1.52	22.17	31.36	31.46	31.58	40.4	44.45	52.8	66.99	5.92	4.77	5.12	6.6	7	25.56	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

한 눈에 저평가된 주식을 인식하세요 fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

가격

가격

티커ALIM

ISINUS0162592028

WKNA2PVHE

Alimera Sciences 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

Alimera Sciences 주가 이력

Alimera Sciences 주식 매출, EBIT, 이익 US0162592028 · A2PVHE

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

Alimera Sciences 매출, 이익 및 EBIT 역사

Alimera Sciences 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

Alimera Sciences 주식 마진 US0162592028 · A2PVHE

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

Alimera Sciences 마진 역사

Alimera Sciences 주식 매출, EBIT, 주당 순이익 US0162592028 · A2PVHE

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Alimera Sciences 매출, 이익 및 EBIT 주당 역사

Alimera Sciences 주식 및 주식 분석

Alimera Sciences Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

Alimera Sciences 역사적인 P/E, EBIT 및 P/S에 따른 평가

Alimera Sciences 주식 수량 US0162592028 · A2PVHE

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Alimera Sciences 주식 분할

Alimera Sciences 수익 예상

Alimera Sciences 수익 놀라움

Alimera Sciences 주식 주주 구조

Alimera Sciences 임원진 및 경영진

Alimera Sciences 주식에 대한 자주 묻는 질문

What values and corporate philosophy does Alimera Sciences represent?

In which countries and regions is Alimera Sciences primarily present?

What significant milestones has the company Alimera Sciences achieved?

What is the history and background of the company Alimera Sciences?

Who are the main competitors of Alimera Sciences in the market?

In which industries is Alimera Sciences primarily active?

What is the business model of Alimera Sciences?

한 눈에 저평가된 주식을 인식하세요
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

티커
ALIM

ISIN
US0162592028

WKN
A2PVHE